| INTRODUCTION
Folate is vital for fetal development. Folic acid supplement use during pregnancy is recommended to prevent neural tube defects, 1 but high dosages have been associated with increased risks of asthma and allergic diseases in animal studies. 2 Human studies that assessed associations of maternal folic acid supplement use or related folate blood concentrations during pregnancy with childhood lung function and asthma show conflicting results. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] This could be due to different methods used to assess folic acid supplement use, including food frequency questionnaires, diet records and self-administered questionnaires, and differences in techniques and ages at which folate concentrations were measured. Besides folic acid use and related folate blood concentrations, vitamin B 12 and homocysteine are involved in the one-carbon metabolism, which is important for DNAmethylation. 13 The one-carbon metabolism is influenced by polymorphisms in the methylenetetrahydrofolate reductase gene (MTHFR). 14, 15 The variant C677T is known to affect the activity of the MTHFR enzyme, leading to lower circulating folate and higher homocysteine concentrations. 16 We previously observed that higher circulating maternal folate concentrations during pregnancy and not at birth were associated with increased risk of atopic dermatitis, 10 but not with wheezing, higher respiratory resistance or fractional exhaled nitric oxide. 4 The modifying effects of maternal or child's MTHFR-C677T variants on the associations of maternal folic acid supplement use during pregnancy with lung function and asthma are less clear. 4, 9, 10 Furthermore, only a limited number of studies assessed the associations of folate, vitamin B12 and homocysteine blood concentrations during pregnancy with lung function and asthma.
Therefore, we aimed to assess in a population-based prospective cohort study the associations of folic acid supplement use and folate, vitamin B 12 and homocysteine concentrations in early pregnancy and at birth with lung function and asthma at age 10 years. Second, we assessed whether these associations were modified by MTHFR-C677T polymorphisms. 17 
| ME TH ODS
This study was embedded in the Generation R Study, a populationbased prospective cohort study from early fetal life onwards situated in Rotterdam, the Netherlands. 18 This study was approved by the Medical Ethical Committee of Erasmus MC, University Medical Center Rotterdam, the Netherlands (MEC_2012-165 NL40020.078.12).
Written informed consent was obtained from parents or legal guardians. Twins, children with missing data on maternal folic acid supplement use and folate, vitamin B 12 and homocysteine concentrations in early pregnancy and at birth (n = 186), and with missing data on lung function and current asthma at age 10 years (n = 1554) were excluded, resulting in a total of 5653 children and their mothers for analyses (Fig. S1 ).
| Maternal folic acid supplement use
In the Netherlands, 400-500 lg folic acid solely or within multivitamin supplements are recommended during pregnancy, and manda- analysed using an immunoelectrochemoluminescence assay on the Architect System (Abbott Diagnostics B.V., Hoofddorp, the Netherlands). 20 The between-run coefficient of variation ranged from 1.5% to 8.9%. Detailed information is provided in the Appendix S1.
| Childhood lung function and asthma
Lung function measures at a median age of 9.7 years (range 8. Respiratory Society) criteria with adequate reach and duration of plateau. We observed no difference in lung function values between the group children with and without stringent criteria and no difference in size or direction of the effect estimates in our analyses when we included or excluded these children. Ever physician-diagnosed asthma, wheezing and use of bronchodilators or inhalant corticosteroids were reported by a parental questionnaire at age 10 years.
Current asthma (no; yes) was defined as ever physician-diagnosed asthma, with either wheezing or the use of inhalant medication in the past 12 months.
| MTHFR-c677t
Maternal DNA was extracted from white blood cells obtained in early pregnancy. Genotyping of MTHFR-C677T was performed using
TaqMan allelic discrimination assay (Applied Biosystems, Foster City, CA, USA) and Abgene QPCR ROX mix (Abgene, Hamburg, Germany). 18 Child's DNA was extracted from white cells in cord blood.
Samples were genotyped using Illumina Infinium II HumanHap610-660 Quad Arrays following standard manufacturer's protocols. Genotype data were extracted from an imputed genomewide association scan (1000G phase Iv3). 18 The imputation quality of MTHFR-C677T
was high (r 2 = .99).
| Covariates
We collected information about maternal age, parity (nulli-; multiparous), history of asthma, eczema or allergy (no; yes) and educational level (low: secondary school or lower; and high: higher than secondary school as highest finished education) from maternal questionnaires at enrollment. Maternal weight and height were measured at enrollment. We obtained information on maternal smoking (no; first trimester only; continued during pregnancy) and alcohol use (no; first trimester only, continued during pregnancy) by multiple questionnaires during pregnancy. Child's sex, gestational age at birth and birthweight were obtained from midwives and hospital records. The country of birth of parents was used to define the child's ethnicity. 22 We measured inhalant allergic sensitization by skin prick test using the "scanned area method", 23 for which detailed information is provided in the Appendix S1.
| Statistical analyses
We used linear and logistic regression models to examine the associa- "low" (SDS <À1.00), "normal" (À1.00≤ SDS ≥1.00) and "high" (SDS >1.00). These groups reflect the 16th and 84th percentile, respectively. The "normal" group was used as reference category. The modifying effects of inhalant allergic sensitization and MTHFR-C677T
polymorphisms were tested by adding them as product terms with the exposures in the models. Models with P-values for interaction <.05
were stratified. Current asthma was reported for 269 children (5.7%). We observed differences in socio-economic characteristics between mothers who the different groups of folic acid supplement use during pregnancy.
Children lost to follow-up had younger, lower educated mothers who smoked more and used less alcohol and were more often of non-European origin, compared to children included (Table S1 ).
| Folic acid supplement use and respiratory outcomes
Maternal folic acid supplement use during pregnancy was associated , forced expiratory flow between 25% and 75% of FVC; FEF 75 , forced expiratory flow at 75% of exhalation. b Not imputed. P-values for differences between different strata of folic acid supplement use were calculated using ANOVA for normal distributed data, Kruskal-Wallis for non-normal distributed data and Pearson chi square to compare distributions within populations. (Table S5) .
At birth, folate concentrations were not associated with lung function or current asthma (Table 4 (Table S6) 
| Comparison with previous studies
Previous studies present conflicting epidemiologic evidence of the effects of maternal folic acid supplement use and folate Values are z-score mean differences or odds ratios (95% confidence intervals) with "never folic acid supplement use during pregnancy" as reference group. "n", number of individuals assessed (lung function) and number of cases/number of individuals assessed (current asthma). Any use of folic acid supplements was categorized into start after the first 10 wk of pregnancy, start within the first 10 wk of pregnancy and preconceptional start. P-value for trend depicts line for increased duration of folic acid supplements use. Lung function variables were converted into sex-, height-, age-and ethnicityadjusted z-scores. FEV 1 , forced expiratory volume in the 1st second; FVC, forced vital capacity; FEF , forced expiratory flow between 25% and 75% of FVC; FEF 75 , forced expiratory flow at 75% of exhalation. Models were adjusted for maternal age and body mass index at intake, parity, history of asthma or atopy, educational level, smoking or alcohol use during pregnancy, child's gestational age at birth, birthweight and ethnicity. *P < .05, **P < .01, **P < .01 (presented in bold).
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| 179 concentrations during pregnancy on risk of childhood asthma. [3] [4] [5] [6] [7] [8] [9] [10] [11] Two studies among 32 077 and >100 000 children showed that folic acid supplement use or folic acid prescription during pregnancy was associated with an up to 1.3-fold increased risks of wheeze and respiratory tract infections up to 18 months of age, 6 and of asthma at ages 4-6 years, 11 respectively. Similarly, in a population-based cohort study among 39 846 children, the higher quintile of maternal total folate intake was associated with an 1.2 increased relative risk of asthma at age 7 years, compared with the lowest quintile. 12 In contrast, a randomized controlled trial among 793 Nepalese children aged 8 years examined the effects of maternal micronutrient supplementation, including folic acid, and observed no differences in childhood FEV 1 , FVC and FEV 1 /FVC between the group with and without supplementation. 25 Results are difficult to generalize to western populations because the Nepalese study assessed multiple micronutrients in a population with depleted micronutrient sources. Folic acid supplement use during pregnancy was not associated with lung function, asthma or atopic outcomes among 1902 Dutch children aged 6-7 years. 3 Higher intracellular folate concentrations in late pregnancy were associated with a lower risk of asthma in a dose-dependent manner.
Results were limited by a small sample size with a low number of asthma cases and a young study population. 26, 27 Studies on the associations of folate, vitamin B 12 and homocysteine concentrations during pregnancy with lung function and asthma are scarce and conflicting. 3, 8, 10, 28 Most studies were limited to an age of asthma diagnosis up to 4 years, which partly is biased by transient wheezing phenotypes. Only folate concentrations in late pregnancy seem to be consistently associated with an increased risk of wheezing and asthma in childhood. 26 A study among 5364 children aged 7-8 years 9 observed no modifying effect of maternal MTHFR-C677T on the associations between folic acid supplement use at 18 and 32 weeks of gestation and risk of asthma and atopic disease. We also observed no associations between MTHFR-C677T genotypes and the risk of childhood asthma.
We did observe that associations of folic acid supplement use in in an excessive incorporation of uracil into DNA and DNA hypomethylation. 33 Experimental studies support the role of folate in cell division, nucleotide synthesis and DNA-methylation during fetal development. 26 Elevated folic acid exposure during pregnancy has been linked to cellular modifications associated with asthma and allergic diseases. 34 In animal models, enriched maternal diet with among others folic acid and vitamin B 12 during pregnancy was associated with epigenetic changes and phenotypic differences in offspring, including immune functioning and insulin resistance, compared with offspring of mothers fed a low methyl donor diet. 34, 35 Human studies are scarce. We previously observed that folate concentrations in early pregnancy were associated with differential DNA-methylation of 443
CpGs linked to 320 genes at birth. 36 These findings suggest that F I G U R E 1 Associations of maternal folic acid supplement use during pregnancy with (A) FEV 1 (B) FVC (C) FEV 1 /FVC (D) FEF (E) FEF 75 and (F) current asthma, for the total population and stratified by maternal and child MTHFR-C677T genotype. Values are z-score mean differences or odds ratios (95% confidence intervals) with "never used folic acid supplements during pregnancy" as reference group. Associations for the entire population and stratification by maternal and child MTHFR-C677T genotype are shown. Lung function variables were converted into sex-, height-, age-and ethnicity-adjusted z-scores. FEV 1 , forced expiratory volume in the 1st second; FVC, forced vital capacity; FEF , forced expiratory flow between 25% and 75% of FVC; FEF 75 , forced expiratory flow at 75% of exhalation. Models were adjusted for maternal age and BMI at intake, parity, history of asthma or atopy, educational level, smoking or alcohol use during pregnancy, child's gestational age at birth, birthweight and ethnicity. *P < .05, **P < .01 DEN DEKKER ET AL. 
| Strengths and limitations
We used a prospective population-based design with a large number of participants being studied from early life with detailed and repeatedly measured exposures and multiple respiratory outcomes.
An association of folic acid supplement use with lung function is supported by our stratified analyses on MTHFR-C677T. This genetic variant has an independent distribution in the population. Therefore, it is unlikely that the differences in associations between folic acid supplement use among mothers with MTHFR-C677T variants and lung function were biased by residual socio-economic and lifestylerelated factors. Still, some limitations do apply. The major source of selection bias in cohort studies usually arises from loss to followup, 37 which was 25.3% in our study. We observed differences in characteristics between included participants and those lost to follow-up and can therefore not fully exclude selection bias. Furthermore, we observed differences in socio-economic characteristics between mothers who the different groups of folic acid supplement use during pregnancy. We adjusted for these differences in the sta- Values are z-score mean differences or odds ratios (95% confidence intervals) with "never folic acid supplement use during pregnancy" as reference group. "n": number of individuals assessed (lung function at age 10 y) and number of cases/number of individuals assessed (current asthma at age 10 y). Lung function variables were converted into sex-, height-, age-and ethnicity-adjusted z-scores. FEV 1 , forced expiratory volume in the 1st second; FVC, forced vital capacity; FEF , forced expiratory flow between 25% and 75% of FVC; FEF 75 , forced expiratory flow at 75% of exhalation; SDS, standard deviations scores. Models were adjusted for maternal age and BMI at intake, parity, history of asthma or atopy, educational level, smoking or alcohol use during pregnancy, child's gestational age at birth, birthweight and ethnicity. Models were stratified for maternal or child MTHFR-C677T carriership when interaction (P-value <.05) was present. No significant interactions were observed between folate, vitamin B 12 and homocysteine concentrations at birth with child MTHFR-C677T carriership. *P < .05, **P < .01 (presented in bold).
and dosage of folic acid supplement use throughout pregnancy.
Therefore, the associations of folate concentrations with lung function and asthma do not reflect the mean daily dosage of folic acid supplement use or folate concentrations throughout pregnancy. Last, analyses stratified on genotype were limited by numbers of asthma cases, which might have led to under-or overestimation of the true effect sizes.
In conclusion, folic acid supplement use during pregnancy was Values are z-score mean differences or odds ratios (95% confidence intervals) with "never folic acid supplement use during pregnancy" as reference group. "n", number of individuals assessed (lung function at age 10 y) and number of cases/number of individuals assessed (current asthma at age 10 y). Lung function variables were converted into sex-, height-, age-and ethnicity-adjusted z-scores. FEV 1 , forced expiratory volume in the 1st second; FVC, forced vital capacity; FEF , forced expiratory flow between 25% and 75% of FVC; FEF 75 , forced expiratory flow at 75% of exhalation; SDS, standard deviations scores. Models were adjusted for maternal age and BMI at intake, parity, history of asthma or atopy, educational level, smoking or alcohol use during pregnancy, child's gestational age at birth, birthweight and ethnicity. Models were stratified for maternal or child MTHFR-C677T carriership when interaction (P-value <.05) was present. No significant interactions were observed between folate, vitamin B 12 and homocysteine concentrations at birth with maternal MTHFR-C677T carriership. *P < .05, **P < .01 (presented in bold).
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